Medifast Inc. (MED) is a leading American nutrition and weight loss management company that offers meal plans and products aimed at promoting healthier living. Publicly traded on the New York Stock Exchange under the symbol MED, the company has carved out a niche for itself in the health and wellness sector with its evidence-based interventions for weight management.
Founded in 1980, Medifast Inc. started its journey in Owings Mills, Maryland, under the insightful leadership of Dr. William Vitale. Initially, the company operated by selling its products directly to doctors, who would then advocate them to patients aiming to manage their weight. However, over time, the company expanded its business model to direct sales to customers via the internet and through call centers.
One of the standout services offered by Medifast Inc. is its well-known 'OPTAVIA' system, which houses a community of like-minded, health-oriented individuals aiming for sustainable weight loss and wellness. The diet plans offered under this program are scientifically designed to provide the necessary nutrients while promoting weight loss through meal replacements.
The extraordinary success of 'OPTAVIA' can be attributed to the fact that clients receive the support of a dedicated coach who guides them through their weight loss journey and helps them make important lifestyle changes. Moreover, the community aspect of the program provides additional motivation and fosters a sense of belonging among its members.
Medifast Inc. has demonstrated consistent growth and success, showcasing its ability to recognize and adapt to market trends in the wellness industry. The company has also shown a strong commitment to quality and safety by investing in scientific research and only sourcing the best ingredients for its products. As a testament to its dedication to promoting good health, the company received BD's Supplier of the Year award in 2020.
Despite the challenging economy and dynamic business environment, Medifast Inc. has remained resilient and robust, demonstrating a strong financial performance with steady revenue growth. Its proven effective approach to weight loss and wellness combined with the strength of its business model have positioned Medifast Inc. as a leader in its industry – a role that it continues to fulfill with great success.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Medifast reported Q3 2026 revenue of $72 million, aligning with guidance and stabilizing around $75 million for the fourth consecutive quarter. The company launched its TriLove brand and Metabolic Health Institute, shifting focus from weight loss to metabolic health, resulting in improved coach productivity despite fewer active coaches. Medifast maintains a strong financial position with $173 million in cash and no debt, targeting profitability in Q4 2026.
Medifast reported a 19.4% year-over-year decline in third-quarter 2026 revenue, reaching $72 million, and a widened net loss of $17.5 million. The company faced a significant drop in active earning coaches, attributed to the rise of GLP-1 weight-loss medications, though average revenue per coach increased. Medifast provided fourth-quarter revenue guidance of $55 million to $75 million and expects full-year revenue between $280 million and $300 million.
Medifast Inc. (MED) reported a third-quarter loss of $17.5 million, or $1.57 per share, with adjusted losses at 19 cents per share. The weight-loss company's revenue for the period was $72 million. Medifast provided a Q4 revenue outlook of $55 million to $75 million and full-year revenue guidance between $280 million and $300 million, expecting a full-year loss ranging from 70 cents to 45 cents per share.
Medifast (NYSE:MED) is anticipated to release its Q3 2026 earnings after market close on Monday, October 26th, with analysts forecasting a loss of $0.35 per share and revenue of $71.30 million. The company's previous quarter surpassed expectations, reporting a smaller loss and higher revenue than predicted. Analyst consensus currently rates Medifast as "Hold" with a $12.00 price target, while insider trading activity has shown both share sales and purchases.